publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Quizartinib
Safety and pharmacokinetics of quizartinib combination therapy with standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia: Results from two phase 1 trials in Japan and China.
T-DXd
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
T-DXd
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: A phase II study protocol (SHAMROCK study)
Other/Multi
HER2-mutant advanced and/or metastatic non-small-cell lung cancer: A US electronic health records database analysis of clinical characteristics, treatment practice patterns, and outcomes
T-DXd
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: A pooled analysis of two phase I studies
Edoxaban
Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients
Edoxaban
Risk factors for bleeding events in Japanese patients with advanced lung cancer: Data from the Rising-VTE/NEJ037 Study
Edoxaban
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial
Edoxaban
Treatment satisfaction and convenience for patients with atrial fibrillation on edoxaban or vitamin K antagonists after transcatheter aortic valve replacement: A post hoc analysis from the ENVISAGE-TAVI AF trial
Edoxaban
Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: A subanalysis of the EMIT-AF/VTE study